MDMB-5Br-INACA

MDMB-5Br-INACA is a synthetic cannabinoid that is also a new psychoactive substance (NPS). It is part of the indazole-3-carboxamide family of synthetic cannabinoids and is believed to act as a potent agonist for the CB1 receptor.

History

MDMB-5Br-INACA was first identified in 2019 in seized drug samples from Japan. It is one of the many synthetic cannabinoids that have been produced in the 21st century for use in "legal high" products, which are often sold as herbal smoking blends or incense.

Pharmacology

Like other synthetic cannabinoids, MDMB-5Br-INACA is believed to act as a potent agonist for the CB1 receptor, which is the primary target of the psychoactive constituent in cannabis, Δ9-tetrahydrocannabinol (THC). However, the exact pharmacology of MDMB-5Br-INACA is still not fully understood.

Legal Status

As of October 2021, MDMB-5Br-INACA is a controlled substance in Japan and is also controlled under analogue laws in various countries including the United States.

See Also

• Synthetic cannabinoids
• Indazole-3-carboxamide
• CB1 receptor
• New psychoactive substance

References

MDMB-5Br-INACA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski